Genetic Signatures Limited (ASX:GSS)

Australia · Delayed Price · Currency is AUD

0.120

-0.020 (-14.29%)

Apr 29, 2026, 10:46 AM AEST

-72.73% (1Y)

Market Cap	31.80M
Revenue (ttm)	19.94M
Net Income (ttm)	-11.27M
Shares Out	227.14M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	528,314
Average Volume	1,230,469
Open	0.140
Previous Close	0.140
Day's Range	0.120 - 0.140
52-Week Range	0.070 - 0.690
Beta	0.52
RSI	55.78
Earnings Date	May 27, 2026

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia. [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2001

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol GSS

Full Company Profile

Financial Performance

In fiscal year 2025, Genetic Signatures's revenue was 19.75 million, an increase of 43.47% compared to the previous year's 13.77 million. Losses were -20.10 million, 12.6% more than in 2024.

Financial Statements

News

Genetic Signatures Earnings Call Transcript: H1 2026

Revenue rose slightly to AUD 8.7 million, but gross margin declined due to higher costs. U.S. expansion remains a focus, with new customers and product development underway, while a forensic review targets cost reductions to address high cash burn.

2 months ago - Transcripts

Genetic Signatures Earnings Call Transcript: H2 2025

Revenue grew 63% to $15.9M with gross margin at 55%, driven by strong respiratory and EMEA sales. Strategic refocus, new automation partnerships, and disciplined cost management position the company for future growth despite a $20.1M loss and slower U.S. uptake.

8 months ago - Transcripts

Genetic Signatures Earnings Call Transcript: H1 2025

Sales rose 136% year-over-year, with gross margin up to 59% and a statutory loss impacted by a one-time impairment. The first U.S. contract was secured, a strong pipeline is in place, and cash reserves exceed AUD 40.7 million.

1 year ago - Transcripts